November 20, 2023 07:04 AM ESTUpdated 03:06 PM

UK pharma industry signs landmark deal with government health service over drug prices

Zachary Brennan

Senior Editor

England’s National Health Service and the pharma industry on Monday morning announced a new five-year deal that will save the NHS £14 billion ($17.4 billion) …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

UK pharma industry signs landmark deal with government health service over drug prices

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

UK phar­ma in­dus­try signs land­mark deal with gov­ern­ment health ser­vice over drug prices

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Ex­clu­sive: To de­vel­op bet­ter cell ther­a­pies for sol­id tu­mors, a new start­up plans to test hun­dreds of them at once

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

UK pharma industry signs landmark deal with government health service over drug prices

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B